YAP1 and McLeod neuroacanthocytosis syndrome: YAP1 has been identified as a molecular target for therapeutic intervention in MLS, and pharmacological inhibition of YAP1 activity with verteporfin has been demonstrated to inhibit MLS cell viability both in vitro and in vivo [45].